CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 13 clinical trials at NIH that match your search criteria

Cancer by type/disease: Kidney (Renal Cell) Cancer

Trial and Protocol Number Kidney (Renal Cell) Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer NCI-10-C-0114, NCT01130519	Ramaprasad Srinivasan 301-496-6353	Geri Hawks 301-402-7913 ghawks@mail.nih.gov
A Phase II Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma NCI-09-C-0057, NCT00820209	Antonio Tito Fojo 301-402-1357	Maureen Edgerly 301-435-5604 edgerlym@mail.nih.gov
Phase I/II
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells NCI-08-C-0088, NCT00923845	Daniel H. Fowler 301-435-8641	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Bladder Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma NCI-12-C-0205, NCT01437488	Andrea B. Apolo 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

Trial and Protocol Number Leiomyomatosis	Principal Investigator	Referral Contact
No Phase
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer NCI-03-C-0066, NCT00055627	W. Marston Linehan 301-496-6353	Lindsay A. Middleton 301-402-7911

Trial and Protocol Number Melanoma	Principal Investigator	Referral Contact
Phase I
A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Metastatic Melanoma and Metastatic Renal Cell Cancer NCI-10-C-0021, NCT01021059	Thomas Waldmann 301-496-6656	Tat’Yana Worthy 301-496-0499 worthyt@mail.nih.gov

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase II
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma NCI-12-C-0098, NCT01502410	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121, NCT00670748	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes NCI-11-C-0013, NCT01218867	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression NCI-13-C-0016, NCT01730118	Lauren V. Wood 301-402-0199	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019, NCT01445509	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

Trial and Protocol Number von Hippel-Lindau Syndrome	Principal Investigator	Referral Contact
Phase II
A Phase II Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors NCI-08-C-0020, NCT00566995	W. Marston Linehan 301-496-6353	Sarah Fowler 301-435-6255 fowlers@mail.nih.gov
No Phase
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders NCI-89-C-0086, NCT00019617	W. Marston Linehan 301-496-6353

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.